Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
6
×
clinical trials
6
×
life sciences
national blog main
san diego blog main
6
×
san diego top stories
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
national
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
amgen
bristol-myers squibb
cancer
eli lilly
fda
fremanezumab
nivolumab
novartis
teva pharmaceutical
alder biopharmaceuticals
calcitonin gene-related peptide
cancer immunotherapy
What
new
6
×
drug
approval
companies
bio
class
drugs
fda
medicines
migraine
roundup
won
advance
advantages
amgen
arguments
bar
big
biogen’s
biologics
biopharmaceutical
biotechs
brings
candidates
club
commercialized
competitors
considered
continued
convo
crop
decades
deliver
developed
diseases
dtx
earlier
exceeded
expect
failures
Language
unset
Current search:
biotech
×
" san diego blog main "
×
" clinical trials "
×
new
×
@xconomy.com
4 years ago
DTx Pharma Raises $10.6M to Advance New Way to Deliver RNA Drugs
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
IPO Wave Rolls On as Five Life Science Firms Haul in $651M
@xconomy.com
6 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines